Caplacizumab
| Monoclonal antibody | |
|---|---|
| Type | Single domain antibody |
| Source | Humanized |
| Target | von Willebrand factor (VWF) |
| Names | |
| Trade names | Cablivi |
| Other names | ALX-0081, caplacizumab-yhdp |
| Clinical data | |
| Main uses | Thrombotic thrombocytopenic purpura (TTP)[1] |
| Side effects | Nosebleeding, headaches, bleeding gums[2] |
| Pregnancy category |
|
| Routes of use | Intravenous, subcutaneous |
| External links | |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a619030 |
| Legal | |
| License data |
|
| Legal status | |
| Chemical and physical data | |
| Formula | C1213H1891N357O380S10 |
| Molar mass | 27876.19 g·mol−1 |
Caplacizumab, sold under the brand name Cablivi, is a medication used to treat thrombotic thrombocytopenic purpura (TTP).[1] It is used with plasma exchange and immunosuppressive therapy.[1] It is given by injection into a vein or under the skin.[2]
Common side effects include nosebleeding, headaches, and bleeding gums.[2] Use in pregnancy may increase the risk of bleeding in the baby.[1] It is a small antibody that attaches to and inactivates von Willebrand factor.[2]
Caplacizumab was approved for medical use in Europe in 2018 and the United States in 2019.[2][1] In the United Kingdom a month of treatment costs about £125,000 as of 2021.[4] This amount in the United States costs about 230,000 USD.[5]
Medical uses
Dosage
It is given at a dose of 10 mg into a vein followed by 10 mg under the skin for at least 30 days.[2]
Mechanism of action
It is an anti-von Willebrand factor humanized immunoglobulin.[6] It acts by blocking platelet aggregation to reduce organ injury due to ischemia.[6]
Chemistry
It is a bivalent single-domain antibody (VHH).
History
The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.[7]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 "Caplacizumab-yhdp Monograph for Professionals". Drugs.com. Retrieved 29 December 2021.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 "Cablivi EPAR". European Medicines Agency (EMA). Archived from the original on 7 June 2020. Retrieved 7 September 2020.
- ↑ "Cablivi 10 mg powder and solvent for solution for injection - Summary of Product Characteristics (SmPC)". (emc). 22 June 2020. Archived from the original on 12 August 2021. Retrieved 22 August 2020.
- ↑ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1081. ISBN 978-0857114105.
- ↑ "Cablivi Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 29 December 2021.
- ↑ 6.0 6.1 "Immune Drug Tackles Microvascular Thrombosis Disorder. February 2016". Archived from the original on 16 January 2021. Retrieved 3 July 2021.
- ↑ "New Drug Therapy Approvals 2019". U.S. Food and Drug Administration. 31 December 2019. Archived from the original on 16 September 2020. Retrieved 15 September 2020.
External links
| External sites: | |
|---|---|
| Identifiers: |
|
 | This monoclonal antibody–related article is a stub. You can help MDWiki by expanding it. |
- Pages using duplicate arguments in template calls
- Use dmy dates from November 2019
- Articles with invalid date parameter in template
- Drugs with non-standard legal status
- Chemical articles with unknown parameter in Infobox drug
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Articles containing unverified chemical infoboxes
- Drugs that are a monoclonal antibody
- Chemicals that do not have a ChemSpider ID assigned
- Monoclonal antibodies
- Sanofi
- Orphan drugs
- RTT
- All stub articles
- Monoclonal antibody stubs